Novel CD20 monoclonal antibodies for lymphoma therapy
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479003/ |
| id |
pubmed-3479003 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-34790032012-10-24 Novel CD20 monoclonal antibodies for lymphoma therapy Cang, Shundong Mukhi, Nikhil Wang, Kemeng Liu, Delong Review Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin’s lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab). BioMed Central 2012-10-11 /pmc/articles/PMC3479003/ /pubmed/23057966 http://dx.doi.org/10.1186/1756-8722-5-64 Text en Copyright ©2012 Cang et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Cang, Shundong Mukhi, Nikhil Wang, Kemeng Liu, Delong |
| spellingShingle |
Cang, Shundong Mukhi, Nikhil Wang, Kemeng Liu, Delong Novel CD20 monoclonal antibodies for lymphoma therapy |
| author_facet |
Cang, Shundong Mukhi, Nikhil Wang, Kemeng Liu, Delong |
| author_sort |
Cang, Shundong |
| title |
Novel CD20 monoclonal antibodies for lymphoma therapy |
| title_short |
Novel CD20 monoclonal antibodies for lymphoma therapy |
| title_full |
Novel CD20 monoclonal antibodies for lymphoma therapy |
| title_fullStr |
Novel CD20 monoclonal antibodies for lymphoma therapy |
| title_full_unstemmed |
Novel CD20 monoclonal antibodies for lymphoma therapy |
| title_sort |
novel cd20 monoclonal antibodies for lymphoma therapy |
| description |
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin’s lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab). |
| publisher |
BioMed Central |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479003/ |
| _version_ |
1611918199372120064 |